147 related articles for article (PubMed ID: 21678421)
1. PML expression in soft tissue sarcoma: prognostic and predictive value in alkylating agents/antracycline-based first line therapy.
Vincenzi B; Santini D; Schiavon G; Frezza AM; Silletta M; Crucitti P; Casali P; Dei Tos AP; Rossi S; Rizzo S; Badalamenti G; Tomasino RM; Russo A; Butrynski JE; Tonini G
J Cell Physiol; 2012 Apr; 227(4):1657-62. PubMed ID: 21678421
[TBL] [Abstract][Full Text] [Related]
2. PML down-regulation in soft tissue sarcomas.
Vincenzi B; Perrone G; Santini D; Grosso F; Silletta M; Frezza A; Rossi S; Russo A; Rabitti C; Gebbia N; Badalamenti G; Casali P; Muda AO; Dei Tos AP; Tonini G
J Cell Physiol; 2010 Sep; 224(3):644-8. PubMed ID: 20578240
[TBL] [Abstract][Full Text] [Related]
3. PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients.
Vincenzi B; Santini D; Perrone G; Graziano F; Loupakis F; Schiavon G; Frezza AM; Ruzzo AM; Rizzo S; Crucitti P; Galluzzo S; Zoccoli A; Rabitti C; Muda AO; Russo A; Falcone A; Tonini G
J Cell Physiol; 2012 Mar; 227(3):927-33. PubMed ID: 21503888
[TBL] [Abstract][Full Text] [Related]
4. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
Sleijfer S; Ouali M; van Glabbeke M; Krarup-Hansen A; Rodenhuis S; Le Cesne A; Hogendoorn PC; Verweij J; Blay JY
Eur J Cancer; 2010 Jan; 46(1):72-83. PubMed ID: 19853437
[TBL] [Abstract][Full Text] [Related]
5. PML protein as a prognostic molecular marker for patients with esophageal squamous cell carcinomas receiving primary surgery.
Yen CC; Tsao YP; Chen PC; Wu YC; Liu JH; Pan CC; Liu CY; Tzeng CH; Chen PM; Chen YJ; Lin CH; Hsu WH
J Surg Oncol; 2011 Jun; 103(8):761-7. PubMed ID: 21240990
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical expression of promyelocytic leukemia body in soft tissue sarcomas.
Matsuo T; Sugita T; Shimose S; Kubo T; Ishikawa M; Yasunaga Y; Ochi M
J Exp Clin Cancer Res; 2008 Nov; 27(1):73. PubMed ID: 19025608
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of the drug resistance-associated protein metallothionein does not correlate with response of sarcomas to isolated limb perfusion treatment.
Grabellus F; Sheu SY; Tötsch M; Lehmann N; Kaiser GM; Jasani B; Taeger G; Schmid KW
J Surg Oncol; 2010 May; 101(6):465-70. PubMed ID: 20401916
[TBL] [Abstract][Full Text] [Related]
8. The comparative role of immunohistochemistry and electron microscopy in the identification of myogenic differentiation in soft tissue pleomorphic sarcomas.
Franchi A; Massi D; Santucci M
Ultrastruct Pathol; 2005; 29(3-4):295-304. PubMed ID: 16036884
[TBL] [Abstract][Full Text] [Related]
9. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
Lee SH; Chang MH; Baek KK; Han B; Lim T; Lee J; Park JO
Oncology; 2011; 80(3-4):257-61. PubMed ID: 21734417
[TBL] [Abstract][Full Text] [Related]
10. Loss of p16(INK4a) is associated with reduced patient survival in soft tissue tumours, and indicates a senescence barrier.
Knösel T; Altendorf-Hofmann A; Lindner L; Issels R; Hermeking H; Schuebbe G; Gibis S; Siemens H; Kampmann E; Kirchner T
J Clin Pathol; 2014 Jul; 67(7):592-8. PubMed ID: 24747207
[TBL] [Abstract][Full Text] [Related]
11. Topoisomerase II-alpha protein expression and histological response following doxorubicin-based induction chemotherapy predict survival of locally advanced soft tissues sarcomas.
Rodrigo RS; Nathalie A; Elodie T; Gonzalo GA; Philippe T; Françoise D; Julien D; Angela C; Bérénice B; Jean-Yves B; Jean-Michel C; Jean B; Sylvie B; Axel le C
Eur J Cancer; 2011 Jun; 47(9):1319-27. PubMed ID: 21450455
[TBL] [Abstract][Full Text] [Related]
12. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients.
Karavasilis V; Seddon BM; Ashley S; Al-Muderis O; Fisher C; Judson I
Cancer; 2008 Apr; 112(7):1585-91. PubMed ID: 18278813
[TBL] [Abstract][Full Text] [Related]
13. Histopathological re-classification of extremity pleomorphic soft tissue sarcoma has clinical relevance.
Massi D; Beltrami G; Capanna R; Franchi A
Eur J Surg Oncol; 2004 Dec; 30(10):1131-6. PubMed ID: 15522563
[TBL] [Abstract][Full Text] [Related]
14. Promyelocytic leukemia (PML) gene expression is a prognostic factor in ampullary cancer patients.
Vincenzi B; Santini D; Perrone G; Russo A; Adamo V; Rizzo S; Castri F; Antinori A; Alloni R; Crucitti PF; Morini S; Rabitti C; Vecchio FM; Magistrelli P; Coppola R; Tonini G
Ann Oncol; 2009 Jan; 20(1):78-83. PubMed ID: 18689862
[TBL] [Abstract][Full Text] [Related]
15. VEGFR2 predicts decreased patients survival in soft tissue sarcomas.
Kampmann E; Altendorf-Hofmann A; Gibis S; Lindner LH; Issels R; Kirchner T; Knösel T
Pathol Res Pract; 2015 Oct; 211(10):726-30. PubMed ID: 26298629
[TBL] [Abstract][Full Text] [Related]
16. Anti-CD10 (56C6) expression in soft tissue sarcomas.
Deniz K; Çoban G; Okten T
Pathol Res Pract; 2012 May; 208(5):281-5. PubMed ID: 22464152
[TBL] [Abstract][Full Text] [Related]
17. Trabectedin in advanced soft tissue sarcoma: case series.
Demirci U; Buyukberber S; Yetisyigit T; Dizdar O; Benekli M; Alkis N; Coskun U;
J BUON; 2012; 17(3):591-2. PubMed ID: 23033305
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of promyelocytic leukemia expression in gastrointestinal stromal tumor; integrated proteomic and transcriptomic analysis.
Ichikawa H; Yoshida A; Kanda T; Kosugi S; Ishikawa T; Hanyu T; Taguchi T; Sakumoto M; Katai H; Kawai A; Wakai T; Kondo T
Cancer Sci; 2015 Jan; 106(1):115-24. PubMed ID: 25457157
[TBL] [Abstract][Full Text] [Related]
19. Expression of multidrug-resistance-associated protein gene in human soft-tissue sarcomas.
Oda Y; Schneider-Stock R; Ryś J; Gruchala A; Niezabitowski A; Roessner A
J Cancer Res Clin Oncol; 1996; 122(3):161-65. PubMed ID: 8601564
[TBL] [Abstract][Full Text] [Related]
20. PML and TRF2 protein expression in hereditary and sporadic colon cancer.
Plevová P; Bouchal J; Fiurásková M; Papezová M; Krepelová A; Curík R; Foretová L; Navrátilová M; Zapletalová J; Posolda T; Kolár Z
Neoplasma; 2007; 54(4):269-77. PubMed ID: 17822315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
